SIGA is monitoring the growing monkeypox outbreak and supports the response

TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox

Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus

Named 27th on the Forbes List of Best Small Cap Companies

Health Security

We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security.

Click here to learn more about how SIGA is monitoring the monkeypox outbreak.
U.S. providers seeking guidance on obtaining TPOXX please visit CDC.gov
For foreign governments or other inquiries about TPOXX (Tecovirimat-SIGA), please contact us at monkeypox@siga.com

(Note: TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox; Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus)

Our Pipeline

Attractive product and market expansion opportunities

Our Team

Experienced team of scientists and business leaders

Our Partners

Rich history of successful partnerships to support our vision

SIGA Technologies Receives Approval from UK for Tecovirimat

Learn More

News & Press Releases

    cURL error 28: Operation timed out after 5000 milliseconds with 0 bytes received